Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 17-21

  Aguilar, L ^a   Balcabao, I P ^b   Salva P ^c   Martin M ^b   Costa, J ^c   Prieto, J ^b   Dal Re R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NORFLOXACIN; RUFLOXACIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTITIS; DOSE RESPONSE; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0030061125     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.17     Document Type: Article

References (36)

1. Aguilar, L., C. Esteban, J. Frias, I. Pérez-Balcabao, A. J. Carcas, and R. Dal-Ré. 1994. Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. J. Antimicrob. Chemother. 33:91-101.
2. Amsterdam, D. 1990. Assessing cidal activity of antimicrobial agents: problems and pitfalls. Antimicrob Newsl. 7:49-56.
3. Craig, W. A., and P. G. Welling. 1977. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications Clin. Pharmacokinet. 2:252-268.
4. Cruciani, M., V. Monzillo, A. Navarra, C. Tinelli, and E. Concia. 1988. Antibacterial activity of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers. Drugs Exp. Clin. Res. 14:533-537.
5. Crumplin, G. L., and J. T. Smith. 1975. Nalidixic acid: an antibacterial paradox. Antimicrob. Agents Chemother. 8:251-261
6. Forrest, A., D. E, Nix, C. H. Ballow, T. F. GOSS, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in senously ill patients. Antimicrob. Agents Chemother. 37:1073-1081
7. Gómez Lus, M. L., S. Barrientos, J. M. Rubias, S. Heredia, M. J. Giménez, and J. Prieto. 1993 Comparative in vitro activity and post-antibiotic effect of rufloxacin. abstr. 430, p. 194. In Abstracts of the 18th International Congress of Chemotherapy.
8. Guglielmo, B. J., and L. C. Rodondi. 1988. Comparison of antibiotic activities by using serum bactericidal activity over time. Antimicrob Agents Chemuther. 32:722-729.
9. Holford, N. 1986. MK model. An extended least-squares modelling program. Elsevier Publishers, Amsterdam
10. Hooton, T, M., C. Johnson, C. Winter, L. Kuwamura, M. E. Rogers. P. L. Roberts, and W. E. Stamm. 1991. Single dose and three das regimens of ofloxacin versus trimetroprim-sulfamethoxazole for acute cystitis in woman. Antimicrob Agents Chemother. 35:1479-1483.
11. Imbimbo, B. P., G. Broccali, M. Cesana, C. Crema, and G. Attardo-Parrinello. 1991. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers Antimicrob. Agents Chemother. 35:390-393
12. Israel, P., J. G. Gillium, M. Turik, K. Harvey, J. Ford, M. Dalton, M. Towle, R. Echols, A. M. Heller, and R. Polk. 1993 Pharmacokinetics and serum bactericidal tilers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers Antimicrob. Agents Chemother. 37:2193-2199
13. Johnson, J. R., and W. E. Stamm. 1987. Diagnosis and treatment of acute urinary tract infections. Infect. Dis. Clin. N. Am. 1:737-791
14. Karabalut, N., and G. L. Drusano. 1993. Pharmacokinetics of the quinolone antimicrobial agents, p 195-223 In D. C Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, D C.
15. Kisicki, J. C., R. S. Griess, C. L. Ott, G. M. Cohem, R. J. McCormack, W. M. Troetel, and B. P. Imbimbo. 1992. Multiple dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother. 36:1296-1301.
16. Klasterky, J., D. Daneau, G. Swings, and D. Weerts. 1974. Antibacterial activity in serum and in urine as a therapeutic guide in bacterial infections. J. Infect. Dis. 129:187-193.
17. Kowalsky, S. F., R. M. Echols, and E. M. McCormick. 1990. Comparative serum bactericidal activity of ceftizoxime/metronidazol, ceftizoxime, clindamicin, and imipenem against obligate anaerobic bacteria. J. Antimicrob. Chemother. 25:767-775.
18. Krogstad, D. J., and R. C. Moellering, Jr. 1988. Antimicrobial combinations, p. 537-595. In V. Lorian (ed.). Antibiotics in laboratory medicine. 2nd ed. The Williams & Wilkins Co., Baltimore.
19. Leggett, J. E., S. A. Wolz, and W. A. Craig. 1989. Use of serum ultrafiltrate in the serum dilution test. J. Infect. Dis. 160:616-623.
20. National Committee for Clinical Laboratory Standards. 1985. Methods for dilution antimicrobial susceptibility tests for bacteria which grow aerobically. Approved standard M7-A. National Committee for Clinical Laboratory Standards, Villanova. Pa.
21. National Committee for Clinical Laboratory Standards. 1987. Methodology for the serum bactericidal test. Proposed guidelines Tentative standard M21-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. Phillips, I., E. Culebras, S. Moreno, and F. Baquero. 1987. Introduction of SOS response by new 4-quinolones. J. Antimicrob. Chemother. 20:631-638.
23. Pien, F. D., R. D. Williams, and K. L. Vosti. 1975 Comparison of broth and human serum as the diluent in the serum bactericidal test. Antimicrob. Agents Chemother. 7:113-114.
24. Ravizzola, G., G. Pinsi, Q. Pirali, D. Colombrita, I. Foresti, L. Peroni, and A. Turano. 1985 Rufloxacin (MF934): in vivo antibacterial activity. Drugs Exp. Clin. Res. 15:11-15.
25. Redington, J., W. Graig, and J. Moffatt. 1991. Does area under the bactericidal curve in serum correlate with the in vivo antimicrobial activity?, abstr. 1193, p. 298. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
26. Ronald, A. R., L. E. Nicolle, and G. K. Harding. 1992 Standards of therapy for urinary tract infections in adults. Infection 20(Suppl 3):164-170
27. Shinkai, S., T. Ogawa, M. Fujita, et al. 1984 The studies on assay method of MT-141 levels in biological fluids. Chemotherapy (Tokyo) 32(Suppl. 5):59-66.
28. Shumaker, R. C. 1986. PKCALC: a basic interactive computer program for statistical and phamiacokinetic analysis of data. Drug Metab. Rev. 17:331-348.
29. Sobel, J. D., and D. Kaye. 1990. Urinary tract infections, p 582-611. In G L. Mandell, R. G. Douglas, and J. E. Bennett (ed.). Principles and practice of infectious diseases. Churchill Livingstone Inc , New York.
30. Stamey, T. A., W. R. Fair, M. M. Timothy, M. A. Millar, G. Mihara, and Y. C. Lowery. 1974. Serum versus antimicrobial concentrations in case of urinary tract infections. N Engl. J Med 291:1159-1163
31. Stamm, W. E., and T. M. Hooton. 1993 Management of urinary tract infection in adults. N Engl. J. Med. 329:1328-1334
32. Stevens, P. I. E. 1980 Bactericidal effect against Eschenchia coli of nalidixic acid and four structurally related compounds. J. Antimicrob. Chemother 6:535-542.
33. Wise, R., J. M. Andrews, R. Matthews, and M. Wolstenholme. 1992. The in vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 29:649-660.
34. Wise, R., D. Griggs, and J. M. Andrews. 1988. Pharmacokinetics of the quinolones in volunteers. A proposed dosing schedule. Rev. Infect. Dis. 10(Suppl. 1):83-89.
35. Wise, R., J. Johnson, N. O'Sullivan, J. M. Andrews, and P. Imbimbo. 1991. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J. Antimicrob Chemother. 28:905-909.
36. Zeiler, M. J., D. Beerman, W. Wingender, D. Föster, and P. Schaht. 1988. Bactericidal activity of ciprofloxacin, norfloxacin, and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection 16(Suppl. 1):S19-S23.